I-mab Biopharma (Hangzhou) Co., Ltd. announced that it will receive equity funding for $19 million from returning investor I-Mab on February 7, 2024. The transaction is expected to be close by the end of March 2024.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.785 USD | -1.38% | +1.42% | -6.05% |
04-18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
04-15 | I-Mab Announces Chief Medical Officer Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-6.05% | 146M | |
+30.95% | 695B | |
+26.51% | 568B | |
-4.65% | 361B | |
+19.51% | 330B | |
+3.89% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+8.44% | 168B |
- Stock Market
- Equities
- IMAB Stock
- News I-Mab
- I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab